FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 417 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... March 25, 2021 Cancer Research UK report highlights stark cancer inequalities across Scotland November 28, 2022 ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... June 23, 2021 For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 Load more HOT NEWS 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Protecting Your Skin From the Sun All Year: Why It’s Important... Cancer Research UK’s charity Christmas cards now available For Esophageal Cancer, Immunotherapy Likely to Play Larger Role
